Pharmamarketeer

AstraZeneca to present phase III data of roxadustat to treat anaemia from CKD at ASN Kidney Week 2019

AstraZeneca will present pooled efficacy and cardiovascular safety analyses from the phase III clinical programme of roxadustat for the treatment of anaemia from chronic kidney disease (CKD) in non dialysis─dependent (NDD) or dialysis─dependent (DD) patients.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl